Article Information
History
- September 6, 2021.
Article Versions
- Version 1 (April 22, 2021 - 16:42).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Nathan Moore1,#,*,
- Rebecca Williams1,#,
- Matilde Mori2,
- Beatrice Bertolusso1,
- Gabrielle Vernet1,
- Jessica Lynch1,
- Peter Philipson3,
- Thomas Ledgerwood1,
- Stephen P. Kidd1,
- Claire Thomas1,
- Veronica Garcia-Arias1,
- Michelle Young4,
- Kordo Saeed2,5,
- Kirsty Gordon1 and
- Nicholas Cortes1,2,6,7
- 1Hampshire Hospitals NHS Foundation Trust, Basingstoke and North Hampshire Hospital, Basingstoke, UK
- 2University of Southampton, School of Medicine, UK
- 3Newcastle University, School of Mathematics, Statistics & Physics, UK
- 4Whittington Hospital, London, UK
- 5University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 6Gibraltar Health Authority, Gibraltar, UK
- 7University of Gibraltar, Gibraltar, UK
- ↵*Corresponding author: Nathan.Moore{at}hhft.nhs.uk, 01256 473202
Posted September 06, 2021.
Mid-Regional pro-Adrenomedullin (MR-proADM), C-Reactive Protein (CRP) and Other Biomarkers in the Early Identification of Disease Progression in COVID-19 Patients in the Acute NHS Setting
